Key clinical point: A regimen consisting of docetaxel and capecitabine (TX) followed by cyclophosphamide, epirubicin, and capecitabine (CEX) prolonged survival in patients with early breast cancer (BC) vs. a regimen containing of only docetaxel followed by cyclophosphamide, epirubicin, and fluorouracil (T-CEF).
Major finding: Patients assigned to TX-CEX vs. T-CEF arms had significantly higher 15-year survival rate (77.6% vs. 73.3%; hazard ratio [HR] 0.81; log-rank P = .037) with patients in the triple-negative subgroup benefitting the most (HR 0.59; 95% CI 0.36-0.97).
Study details: Findings are from the open-label, phase 3 FinXX study including 1,495 patients with axillary node-positive or high-risk node-negative early BC, who were randomly assigned to the TX-CEX or T-CEF arms.
Disclosures: This study was supported by Roche, Sanofi, AstraZeneca, the Cancer Society of Finland, and others. The authors declared serving as consultants, advisors, or on the speaker’s bureau or receiving honoraria and research funding from several sources.
Source: Joensuu H et al. J Clin Oncol. 2022 (Jan 12). Doi: 10.1200/JCO.21.02054.